Medical Equipment

Companion Diagnostics Industry Forecast to Hit $18.78 Billion by 2029 With a Strong 21.2% CAGR

November 14, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Companion Diagnostics Market Size During 2025–2029?

The market encompassing companion diagnostics has experienced swift expansion lately, projected to advance from a valuation of $7.34 billion in 2024 to $8.69 billion in the subsequent year, marking an 18.4 percent compound annual growth rate. This upward trajectory throughout the historical span is fundamentally linked to wider integration of tailored medical treatments, the expanding scope of oncology and cancer-related therapeutics, heightened partnership in pharmaceutical research and development, the push towards precise medical approaches, and ongoing efforts in biomarker identification.

Exponential expansion is projected for the companion diagnostics sector over the immediate future, anticipated to reach a valuation of $18.78 billion by 2029, driven by a compound annual growth rate (CAGR) registering at 21.2%. This forthcoming surge in market size is largely fueled by advancements in targeted therapy creation, the growing need for infectious disease detection mechanisms, expansion in diagnostics for infrequently occurring conditions, the rising use of biomarkers in drug development, the proliferation of point-of-care testing solutions, and the increasing utilization of liquid biopsy techniques. Key developments shaping this period encompass strides in immunotherapy and immunology research, the integration of artificial intelligence and machine learning methodologies within diagnostic processes, a rise in novel product introductions, the implementation of Industry 4.0 principles, and the forging of strategic partnerships among industry players.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7038&type=smp

What Are The Drivers Pushing New Developments In The Companion Diagnostics Market?

Anticipated expansion of the companion diagnostics sector is being fueled by the rising prevalence of targeted therapeutic approaches. Targeted therapy represents a medicinal intervention designed to specifically address unique attributes of malignant cells to impede the proliferation and dissemination of the ailment; these drugs travel systemically but exert a more focused impact compared to traditional chemotherapy, often resulting in reduced negative side effects. The utilization of companion diagnostic assessments guided by biological markers for these targeted cancer treatments is rapidly establishing itself as a critical component of individualized oncology management. As an illustration, data from the Personalised Medicine Coalition, a US healthcare organization, indicated that the FDA granted approvals for sixteen novel personalized treatments in 2023 for individuals suffering from rare diseases, which marked a significant increase from the six approvals recorded in 2022. Consequently, this escalating adoption of targeted therapies is directly contributing to the advancement of the companion diagnostics market.

Which Key Segments Fueling The Companion Diagnostics Market?

The companion diagnosticsmarket covered in this report is segmented –

1) By Product And Service: Assays, Kits And Reagents, Software And Services

2) By Technology: Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry

3) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma

4) By End-User: Pharmaceutical And Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations

Subsegments:

1) By Assays: Polymerase Chain Reaction (PCR) Assays, Immunohistochemistry (IHC) Assays, Next-Generation Sequencing (NGS) Assays, In Situ Hybridization (ISH) Assays

2) By Kits And Reagents: Diagnostic Kits, Detection Reagents, Control Reagents

3) By Software And Services: Data Analysis Software, Interpretation Software, Custom Development Services, Consulting and Support Services

Which Competitive Trends Are Defining The Companion Diagnostics Market Structure?

A major trajectory within the field of companion diagnostics involves ongoing technological progress; specifically, artificial intelligence integration is being leveraged for the creation of more effective therapeutic agents relevant to companion diagnostics. This extensive utilization of AI has been made feasible by the constant accumulation of substantial data originating from varied genetic assessment procedures. Taking a concrete example, Deep Genomics, a firm established in Toronto, applies artificial intelligence methodologies to identify superior pharmaceutical options for hereditary conditions and accelerate their progression into human testing phases. Their objective centers on deploying deep learning algorithms to thoroughly investigate the human genome, thereby gaining insights into disease etiology and subsequently designing and validating chemical entities suitable for therapeutic intervention. Through computational modeling driven by deep learning, scientific researchers possess the capability to evaluate countless chemical structures, zeroing in on viable compositions destined to become life-saving pharmaceuticals accessible to a global population.

Which Major Industry Participants Are Leading The Companion Diagnostics Market Growth?

Major companies operating in the companion diagnostics market include F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Abnova Corp., Amoy Diagnostics Co. Ltd., ARUP Laboratories, Bayer AG, Biomerieux SA, Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Caris Life Sciences, Cepheid Inc., Diaceutics plc, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sividon Diagnostics GmbH, Sysmex Corporation, Ventana Medical Systems, Vermillion Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

What Are The Key Regional Factors Influencing The Companion Diagnostics Market Growth?

North America was the largest region in the companion diagnostics market in 2024. The regions covered in the companion diagnostics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Companion Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=7038&type=smp

Browse Through More Reports Similar to the Global Companion Diagnostics Market 2025, By The Business Research Company

Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Point Of Care Diagnostics Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report

Molecular Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795